Pavlo Kot

Vir Biotechnology appoints David Liu as executive vice president and chief medical officer

Vir Biotechnology appoints David Liu as executive vice president and chief medical officer
Vir Biotechnology names new CMO

Vir Biotechnology has named David Liu as executive vice president and chief medical officer. The company stated that Liu brings significant experience in immuno-oncology and global regulatory strategies as Vir Biotechnology advances therapies for cancer and chronic Hepatitis Delta.

The appointment marks a strategic leadership move as the company continues to develop pipeline therapies targeting critical disease areas.

In March, Vir Biotechnology named Aziz Sawaf as executive vice president and chief financial officer with oversight of finance, operations, IT, and investor relations, according to company disclosures. The company recently presented expanded Phase 2 data on its oral therapies for chronic Hepatitis Delta at a conference in Denver, as detailed in previous announcements. These developments come as Vir advances its leadership and clinical programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.